Jaguar Health to present crofelemer POC study results in investor webcast

Jaguar Health’s (JAGX) Napo Pharmaceuticals and Napo Therapeutics announced that Jaguar is hosting an investor webcast on Wednesday, April 30, 2025 at 8:30 AM Eastern to review the initial results of the proof-of-concept investigator-initiated trial of a novel liquid formulation of crofelemer, Jaguar’s plant-based anti-secretory prescription drug, in patients with the rare diseases microvillus inclusion disease and short bowel syndrome with intestinal failure that were presented by Dr. Mohamad Miqdady on April 26, 2025 at the 11th Annual ELITE PED-GI Congress in Abu Dhabi in the United Arab Emirates. The webcast will include commentary from the following KOLs: Dr. Mohamad Miqdady, a recognized leader in pediatric gastroenterology who is Sheikh Khalifa Medical City’s Division Chief of the Pediatric Gastroenterology, Hepatology & Nutrition Division, and the primary investigator for the ongoing exploratory, single-arm open label non-randomized trial of crofelemer in Abu Dhabi; Dr. Christos Tzivinikos, Founder of the Pediatric GI Department at Al Jalila Children’s Specialty Hospital in Dubai, and an Adjunct Clinical Assistant Professor at Mohammed Bin Rashid University of Medicine and Health Sciences in Dubai; Pravin Chaturvedi, PhD, Chair of Napo’s and Jaguar’s Scientific Advisory Board and Jaguar’s Chief Scientific Officer, who chaired a session at the ELITE PED-GI Congress. This study is being conducted at SKMC, a flagship tertiary hospital in the United Arab Emirates and the largest teaching medical center in Abu Dhabi, by Dr. Miqdady, a recognized leader in pediatric gastroenterology who is SKMC’s Division Chief of the Pediatric Gastroenterology, Hepatology & Nutrition Division. He is an American board-certified pediatric GI, hepatology and nutrition professor at Khalifa University in Abu Dhabi, and serves as a member of Napo’s SAB. Dr. Miqdady completed his Fellowship in Pediatric Gastroenterology at Baylor College of Medicine and Texas Children’s Hospital in Houston. Jaguar is currently supporting three POC IITs, and conducting two placebo-controlled Phase 2 studies, for crofelemer for SBS-IF and/or MVID patients in the United States, European Union, and/or Middle East/North Africa regions. The company’s Phase 2 study to evaluate the efficacy of crofelemer for MVID in pediatric patients has been initiated, as has the company’s Phase 2 study to evaluate the efficacy of crofelemer for SBS-IF in adults. As with the POC IIT of crofelemer in Abu Dhabi in pediatric patients for various CDDs, including SBS-IF or MVID, the independent IIT in the U.S. to evaluate crofelemer for SBS-IF in adults has also begun treating the first patient. The additional IIT is expected to initiate in Q2 2025. Additional POC results from IITs are expected throughout 2025 and will provide additional preliminary data on the safety and potential effectiveness of crofelemer for these highly unmet clinical needs. In accordance with the guidelines of specific EU countries, published data from clinical investigations in MVID and SBS-IF could support reimbursed early patient access to crofelemer for these debilitating conditions.